SynthesisJournal of neurology2021
A global view of comorbidity in multiple sclerosis: a systematic review with a focus on regional differences, methodology, and clinical implications.
Synthesis in Journal of neurology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 2 syntheses or guidelines pooled it, 84 citations in OpenAlex.
- Measures of Comorbidities and Frailty in Multiple Sclerosis-Systematic Review on Evidence and Applicability of Utilized Scoring Systems in Clinical Routine and Real-World Data.European journal of neurology · 2025Pooled it
- The prevalence and risk factors of anxiety in multiple sclerosis: A systematic review and meta-analysis.Frontiers in neuroscience · 2023Pooled it
- E-based physical exercise in patients with multiple sclerosis and comorbidity (COMPACT): feasibility study and protocol for a randomized controlled trial.Frontiers in immunology · 2026Trial
- Genome-wide association analyses highlight the neuronal contribution to multiple sclerosis susceptibility.Nature genetics · 2026Article
- Comorbid autoimmune diseases do not influence long-term disability progression in multiple sclerosis.Acta neurologica Belgica · 2026Article
- Effects of Transcutaneous Spinal Direct Current Stimulation on Cognitive and Psychological Outcomes in Multiple Sclerosis: A Preliminary Case Series.Biomedicines · 2026Article
- Psychometric characteristics of the Persian version of the Dissociative Experiences Scale (DES-II) in patients with multiple sclerosis (PWMS).Discover mental health · 2026Article
- Effects of exercise training among adults with multiple sclerosis: protocol for a systematic review that informs an updated prescriptive guideline.Systematic reviews · 2026Article
- Comorbidity and modifiable risk factors in multiple sclerosis.Therapeutic advances in neurological disorders · 2026Review
- Frailty, urinary symptoms, comorbidity and multiple sclerosis.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025Article
- Timing and Predictive Value of Clinical Conditions Preceding Multiple Sclerosis in the UK Biobank.Annals of clinical and translational neurology · 2025Article
- Treatment Options for the Comorbidity of Multiple Sclerosis with Other Chronic Inflammatory Diseases.Deutsches Arzteblatt international · 2025Review
- Exploring the Perspectives of Healthcare Consumers Towards the Integration of Nutrition in Routine Multiple Sclerosis Care: A Qualitative Study.Journal of human nutrition and dietetics : the official journal of the British Dietetic Association · 2025Article
- Effect of autoimmune comorbidities on multiple sclerosis course: An observational multicenter study.European journal of neurology · 2025Observational
- Prevalence of Stroke in People with Multiple Sclerosis.International journal of preventive medicine · 2025Article
- An Association of Framingham Risk Score with Patient Determined Disease Steps in a Cohort of Relapsing-Remitting Multiple Sclerosis Patients: An Italian Real-World Monocentric Experience.Current neuropharmacology · 2025Observational
- GWAS highlights the neuronal contribution to multiple sclerosis susceptibility.medRxiv : the preprint server for health sciences · 2024Article
- Impact of Ocrelizumab on Disease Progression, Memory Improvement, and Quality of Life in Patients with Relapsing-Remitting Multiple Sclerosis: A Longitudinal MRI and Clinical Criteria Analysis.Diseases (Basel, Switzerland) · 2024Article
- Dietary Modification Combined with Nutrition Education and Counseling for Metabolic Comorbidities in Multiple Sclerosis: Implications for Clinical Practice and Research.Current nutrition reports · 2024Review
- The Prevalence of Comorbidities and Their Association With Disability Progression in Individuals With Multiple Sclerosis: A Study From Brazil.International journal of MS care · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple sclerosis (MS) is a chronic autoimmune disorder of the central nervous system which is associated with numerous comorbidities. These include cardiovascular disease, psychiatric and neurologic disturbances, restless leg syndrome, migraine, cancer, autoimmune diseases, and metabolic disorders. Comorbid disease is an important consideration for clinicians treating patients with MS; early presentation of comorbidities can obscure or delay MS diagnosis, as well as significantly impacting the disease course. Improved understanding of comorbidities and their emergence in MS populations is important for improving the quality of life and optimizing treatment for patients. Therefore, we evaluated published studies reporting epidemiologic data on comorbidities and their associated impact on disease progression in patients with MS (PwMS). The prevalence of neurologic, cardiovascular, metabolic, and autoimmune comorbidities was elevated in PwMS in general, and furthermore, this adversely affected a broad range of outcomes. Compared with PwMS, cancer rates in people without MS or the general population were lower, which should prompt further studies into the mechanisms of both diseases. Studies were under-represented in many regions owing to the latitudinal gradient of MS and possible underfunding of studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.